Table 3.
Most frequently evaluated antithrombotics in clinical trials for COVID-19 a.
| Therapy | Type | Mechanism | No. of Interventional Clinical Trials b |
|---|---|---|---|
| Unfractionated heparin or Low molecular weight heparins (Enoxaparin, Dalteparin, Tinzaparin, and others) | Sulfated glycosaminoglycans | Activation of antithrombin to inhibit thrombin and factor Xa | ~23 |
| Aspirin (Acetylsalicylic acid) | Small molecule | Cyclo-oxygenase inhibitor | ~8 |
| Rivaroxaban (Xarelto) |
Small molecule | Direct factor Xa inhibitor | ~5 |
| Dipyridamole (Aggrenox) |
Small molecule | Nucleoside transport inhibitor and a phosphodiesterase 3 inhibitor | ~3 |
| Clopidogrel (Plavix) |
Small molecule | Irreversible adenosine diphosphate receptor blocker | ~3 |
a From clinicaltrials.gov, b No. is as of 25 July 2020.